BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines
May 13, 2020 07:00 ET | The Sabin Vaccine Institute
WASHINGTON, D.C. and ROME, Italy, May 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and...
GOVX new logo.png
GeoVax Publishes Ebola Vaccine Study Results in Nature’s Scientific Reports
January 16, 2018 09:00 ET | GeoVax, Inc.
ATLANTA, GA, Jan. 16, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced publication of its manuscript entitled “A...
AbCellera Announces Successful Completion of Collaboration for the Discovery of Fully Human Antibodies Against Pathogenic E. Coli and Ebola Virus
January 20, 2016 19:13 ET | AbCellera
VANCOUVER, British Columbia, Jan. 20, 2016 (GLOBE NEWSWIRE) -- AbCellera announced today successful completion of its first antibody discovery partnership with MassBiologics of the University...
MMRGlobal to Grant Royalty-Free Licenses to Universities to Research Ebola Therapies Using Company's Patented Monoclonal Antibody Technology
August 05, 2014 08:35 ET | MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Aug 5, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the Company plans on granting royalty-free licenses to universities interested in using the...